The global demineralized bone matrix (DBM) market is expected to have a US$ 702,29 million global market in 2023, rising to US$ 920,84 million by 2030 at a projected compound yearly growth rate of 5.6%. The growth of the market is driven by the increasing demand for bone graft substitutes in orthopedic and spine surgeries. DBM is a natural bone graft substitute that is derived from human or animal bone. It is processed to remove the inorganic minerals, leaving behind a collagen matrix that promotes bone growth.

Within the larger medical and orthopedic business, the demineralized bone matrix (DBM) market is a dynamic subsector. DBM is a bio-implantation material generated from allogeneic bone that has undergone processing to eliminate mineral content while preserving vital organic elements. The end product is a matrix that is abundant in proteins, collagen, and growth factors that support the regeneration and healing of broken bones.

Request A Sample Copy of This Research Report! https://absolutemarketresearch.com/Global-Demineralized-Bone-Matrix-(DBM)-Market/1236/request-sample

The market for demineralized bone matrix is anticipated to grow quickly due to developments in grafting and an increase in cosmetic surgery. In addition, the younger population and athletes' growing need for surgical treatments and soft tissue allografts will definitely propel this industry ahead. A comprehensive analysis of the market is given in the Global Demineralized Bone Matrix Market study. The study provides a thorough examination of the market's major segments, trends, drivers, constraints, competitive environment, and other elements that are significantly influencing it.

Definition of the Global Demineralized Bone Matrix Market:

An allograft bone that has had the inorganic mineral removed, leaving just the organic "collagen" matrix, is known as demineralized bone matrix (DBM). In 1965, Marshall Urist made the initial discovery that more biologically active bone morphogenetic proteins are revealed when bone minerals are removed. The development of progenitor cells into osteoprogenitor cells, which are in charge of creating bone and cartilage, is influenced by these growth factors. Because of the demineralization process, DBM has much lower mechanical qualities but is more physiologically active than demineralized bone transplants.

The success of a bone graft depends on its capacity to draw host cells to the graft site and control how they differentiate into osteoblasts, which produce new bone, to heal the deficiency. The osteoconductive, osteoinductive, and osteogenic qualities of the transplant will dictate this. Autograft bone taken from the iliac crest is currently regarded as the "gold standard" due to its superior osteogenic qualities. Its application is, however, restricted by donor site morbidity, lengthier surgical and recuperation periods, and a shortage of donor bone.

Allograft bone has the potential to replace autograft bone. It needs to be extensively treated and terminally sterilized before implantation in order to reduce the possibility of an immunological reaction or the spread of illness. During this process, the graft's osteogenic and osteoinductive qualities are eliminated, leaving just an osteoconductive scaffold. These scaffolds come in a range of preparations (such struts and morselized particles) for different orthopedic uses. Since the mineral is removed, DBM's biological qualities are superior to those of demineralized allograft bone, hence enhancing the graft's osteoinductivity.

Key Takeaways:

  • The global demineralized bone matrix (DBM) market is expected to have a US$ 702,29 million global market in 2023, rising to US$ 920,84 million by 2030 at a projected compound yearly growth rate of 5.6%.
  • The growth of the market is being driven by the increasing demand for bone graft substitutes in orthopedic and dental applications.
  • North America is the largest market for DBM, followed by Europe and Asia Pacific.
  • The increasing prevalence of bone-related disorders, such as osteoporosis and osteoarthritis, is also driving the growth of the market.

Regional Outlook:

  • North America is the largest market for DBM, owing to the high prevalence of bone-related disorders and the increasing adoption of minimally invasive surgical procedures.
  • Europe is the second-largest market for DBM, driven by the growing demand for regenerative medicine products.
  • Asia Pacific is the fastest-growing market for DBM, due to the rising disposable incomes and the increasing awareness of bone graft substitutes.

Key Players:

  • Stryker Corporation
  • Zimmer Biomet
  • RTI Surgical
  • Ossur
  • MiMedx
  • Amedica Corporation
  • Geistlich Biomaterials
  • Bioventus
  • Globus Medical
  • Depuy Synthes

Segmentation:

By type:

  • Purified DBM
  • Injectable DBM
  • Putty DBM
  • Strip DBM

By application:

  • Spine surgery
  • Orthopedic surgery
  • Dental surgery

By region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa